India Globalization Capital Inc. (IGC) News
Filter IGC News Items
IGC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IGC News Highlights
- IGC's 30 day story count now stands at 3.
- Over the past 13 days, the trend for IGC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about IGC are MD, DRUG and JPM.
Latest IGC News From Around the Web
Below are the latest news stories about IGC PHARMA INC that investors may wish to consider to help them evaluate IGC as an investment opportunity.
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’sPOTOMAC, Md., December 19, 2023--Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s |
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024POTOMAC, Md., December 13, 2023--IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024 |
IGC Pharma Announces Collaboration to Integrate AI into Clinical TrialsPOTOMAC, Md., December 06, 2023--IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University’s Center for Research and Training in Artificial Intelligence ("CINFONIA"). The partnership aims to leverage Generative AI (AI) to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of trea |
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI InitiativesPOTOMAC, Md., November 21, 2023--IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives |
IGC Pharma Reports Second Quarter Fiscal 2024 ResultsPOTOMAC, Md., November 13, 2023--IGC Pharma Reports Second Quarter Fiscal 2024 Results. |
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief TherapyPOTOMAC, Md., October 19, 2023--IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy. |
IGC Announces Results of its 2023 Annual Stockholders MeetingPOTOMAC, Md., August 21, 2023--IGC Announces Results of its 2023 Annual Stockholders Meeting |
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical TrialsPOTOMAC, Md., August 14, 2023--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate. |
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto RicoPOTOMAC, Md., August 02, 2023--IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico |
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International ConferencePOTOMAC, Md., July 18, 2023--IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer’s Association International Conference. |